Clinical Trial Update: A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

View source ↗

Summary

A study assessing adherence to apalutamide in men with metastatic hormone-sensitive prostate cancer in France is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ERLEADA (apalutamide)

Snippet

Sponsor: Janssen Cilag S.A.S. | Conditions: Prostatic Neoplasms, Metastatic Hormone-sensitive Prostate Cancer | Status: RECRUITING